-
Innovation Ranking
NewInnovation Ranking – Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc (Lineage) formerly known as BioTime Inc, is a clinical-stage biotechnology company that develops new cell therapies for unmet medical needs. It develops products based on its core proprietary technology cell-based therapy platform. The company focuses on developing new cellular therapies for neurological conditions associated with demyelination and degenerative retinal diseases. Lineage’s lead product Renevia is developed for the treatment of facial lipoatrophy and HIV lipoatrophy. Its pipeline products include OpRegen for advanced dry age-related macular degeneration,...
-
Product Insights
Lineage LGC – Calgary Cold Storage Facility Expansion – Alberta
The Lineage LGC – Calgary Cold Storage Facility Expansion – Alberta project involves the expansion of an 18,581m2 cold storage facility in Calgary, Alberta, Canada. Equip yourself with the essential tools needed to make informed and profitable decisions with our Lineage LGC – Calgary Cold Storage Facility Expansion – Alberta report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and...
-
Product Insights
NewNet Present Value Model: Lineage Cell Therapeutics Inc’s OpRegen
Empower your strategies with our Net Present Value Model: Lineage Cell Therapeutics Inc's OpRegen report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Lineage Cell Therapeutics Inc’s OPC-1
Empower your strategies with our Net Present Value Model: Lineage Cell Therapeutics Inc's OPC-1 report and make more profitable business decisions.Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Lineage Cell Therapeutics...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Revumenib Citrate in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Revumenib Citrate in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Revumenib Citrate in Refractory Acute Myeloid Leukemia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Revumenib Citrate in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Revumenib Citrate in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Revumenib Citrate in Relapsed Acute Myeloid Leukemia Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Revumenib Citrate in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Revumenib Citrate in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Revumenib Citrate in Metastatic Colorectal Cancer Drug Details: Revumenib citrate...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Revumenib Citrate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Revumenib Citrate in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Revumenib Citrate in Solid Tumor Drug Details: Revumenib citrate (SNDX-5613) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PCART7 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PCART7 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PCART7 in Acute Lymphocytic Leukemia (ALL, Acute...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pinometostat in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pinometostat in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pinometostat in Refractory Acute Myeloid Leukemia Drug Details: Pinometostat (EPZ-5676)...